Works matching AU Bjørn, Mads Emil

Results: 13

Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis.

Published in:

Cancer Medicine, 2018, v. 7, n. 8, p. 3571, doi. 10.1002/cam4.1619

By:

Mikkelsen, Stine Ulrik;
Kjær, Lasse;
Bjørn, Mads Emil;
Knudsen, Trine Alma;
Sørensen, Anders Lindholm;
Andersen, Christen Bertel Lykkegaard;
Brochmann, Nana;
Skov, Vibe;
Hasselbalch, Hans Carl;
Bjerrum, Ole Weis;
Fassi, Daniel El;
Nielsen, Claus Henrik;
Kruse, Torben A.;
Thomassen, Mads;
Larsen, Thomas Stauffer;
Mourits‐Andersen, Hans Torben;
Pallisgaard, Niels

Publication type:

Article

Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort.

Published in:

Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01150-3

By:

Enemark, Marie Hairing;
Hemmingsen, Jonas Klejs;
Andersen, Maja Dam;
Hybel, Trine Engelbrecht;
Bjørn, Mads Emil;
Josefsson, Pär Lars;
Pedersen, Lars Møller;
Juul, Maja Bech;
Pedersen, Robert Schou;
Thorsgaard, Michael;
Sillesen, Ida Blok;
Plesner, Trine Lindhardt;
Hamilton-Dutoit, Stephen Jacques;
Jensen, Paw;
Madsen, Charlotte;
Ludvigsen, Maja

Publication type:

Article

Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase.

Published in:

Journal of Enzyme Inhibition & Medicinal Chemistry, 2017, v. 32, n. 1, p. 1203, doi. 10.1080/14756366.2017.1368505

By:

Damgaard, Dres;
Bjørn, Mads Emil;
Jensen, Peter Østrup;
Nielsen, Claus Henrik

Publication type:

Article

Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis.

Published in:

Leukemia & Lymphoma, 2019, v. 60, n. 10, p. 2549, doi. 10.1080/10428194.2019.1579323

By:

Bjørn, Mads Emil;
Brimnes, Marie Klinge;
Gudbrandsdottir, Sif;
Andersen, Christen Lykkegaard;
Poulsen, Henrik Enghusen;
Henriksen, Trine;
Hasselbalch, Hans Carl;
Nielsen, Claus Henrik

Publication type:

Article

Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.

Published in:

Leukemia & Lymphoma, 2016, v. 57, n. 1, p. 125, doi. 10.3109/10428194.2015.1046867

By:

Bjørn, Mads Emil;
Holmström, Morten Orebo;
Hasselbalch, Hans Carl

Publication type:

Article

Reduced glutathione as a physiological co-activator in the activation of peptidylarginine deiminase.

Published in:

Arthritis Research & Therapy, 2016, v. 18, p. 1, doi. 10.1186/s13075-016-1000-7

By:

Damgaard, Dres;
Bjørn, Mads Emil;
Steffensen, Maria A.;
Pruijn, Ger J. M.;
Nielsen, Claus H.

Publication type:

Article

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.

Published in:

Mediators of Inflammation, 2015, v. 2015, p. 1, doi. 10.1155/2015/102476

By:

Hasselbalch, Hans Carl;
Bjørn, Mads Emil

Publication type:

Article

The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms.

Published in:

Mediators of Inflammation, 2015, v. 2015, p. 1, doi. 10.1155/2015/648090

By:

Bjørn, Mads Emil;
Hasselbalch, Hans Carl

Publication type:

Article

The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms.

Published in:

Clinical Case Reports, 2015, v. 3, n. 6, p. 499, doi. 10.1002/ccr3.281

By:

Bjørn, Mads Emil;
Hasselbalch, Hans Carl

Publication type:

Article

Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.

Published in:

Expert Review of Hematology, 2017, v. 10, n. 5, p. 393, doi. 10.1080/17474086.2017.1284583

By:

Bjørn, Mads Emil;
Hasselbalch, Hans Carl

Publication type:

Article

Severity and 90-day survival of SARS-CoV-2 infection among patients with haematological disorders.

Published in:

Acta Oncologica, 2022, v. 61, n. 4, p. 500, doi. 10.1080/0284186X.2022.2026464

By:

Glenthøj, Andreas;
Jakobsen, Lasse H.;
Bjørn, Mads Emil;
Poulsen, Christian B.;
Sengeløv, Henrik;
Severinsen, Marianne T.;
Qvist, Kristian;
Overgaard, Ulrik M.;
Ahmad, Syed A.;
Rewes, Annika;
Mølle, Ingolf;
Strandholdt, Casper N.;
Kodahl, Annette R.;
Ryg, Jesper;
Brieghel, Christian;
Johansen, Isik S.;
Kannik, Karina;
Jensen-Fangel, Søren;
Wiese, Lothar;
Kirk, Ole

Publication type:

Article

B‐cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon‐α2, or combination treatment.

Published in:

European Journal of Haematology, 2019, v. 103, n. 4, p. 351, doi. 10.1111/ejh.13292

By:

Sørensen, Anders Lindholm;
Bjørn, Mads Emil;
Riley, Caroline H.;
Holmstrøm, Morten;
Andersen, Mads Hald;
Svane, Inge Marie;
Mikkelsen, Stine Ulrik;
Skov, Vibe;
Kjær, Lasse;
Hasselbalch, Hans C.;
Nielsen, Claus H.

Publication type:

Article

Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state.

Published in:

European Journal of Haematology, 2014, v. 93, n. 3, p. 224, doi. 10.1111/ejh.12332

By:

Bjørn, Mads Emil;
Andersen, Christen Lykkegaard;
Jensen, Morten Krogh;
Hasselbalch, Hans C.

Publication type:

Article